ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 57396771 |
| CHEMBL ID | 1922174 |
| CHEBI ID | 168298 |
| MeSH ID | M0556627 |
| Synonym |
|---|
| ganoderic acid c2 |
| (2r,6r)-2-methyl-4-oxo-6-[(3s,5r,7s,10s,13r,14r,15s,17r)-3,7,15-trihydroxy-4,4,10,13,14-pentamethyl-11-oxo-1,2,3,5,6,7,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid |
| CHEBI:168298 |
| CHEMBL1922174 , |
| bdbm50359040 |
| 103773-62-2 |
| AC-34472 |
| 3,7,15-trihydroxy-11,23-dioxo-, (3b,7b,15a,25r)- |
| lanost-8-en-26-oicacid |
| ganoderic acid c 2 |
| lanost-8-en-26-oicacid, 3,7,15-trihydroxy-11,23-dioxo-, (3b,7b,15a,25r)- |
| HY-N1517 |
| CS-0017060 |
| MS-29623 |
| ganodericacidc2 |
| AKOS040760408 |
| Class | Description |
|---|---|
| triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 (µMol) | 43.8000 | 0.0010 | 1.1913 | 10.0000 | AID631922 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tumor necrosis factor | Homo sapiens (human) | Kd | 0.0084 | 0.0027 | 4.2926 | 9.7700 | AID1156798 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1156798 | Binding affinity to TNF-alpha (unknown origin) | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking. |
| AID1156800 | Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking. |
| AID1551892 | Tmax in Sprague-Dawley rat at 300 mg/kg, po by LC-ESI-IT-TOF/MS analysis | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y. |
| AID779722 | Inhibition of alpha-glucosidase (unknown origin) using sucrose as substrate assessed as formation of glucose after 30 mins by glucose oxidase method | 2013 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21 | Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors. |
| AID1156795 | Retention time of the compound by chromatography | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking. |
| AID631922 | Inhibition of recombinant human aldose reductase using dl-glyceraldehyde as substrate after 10 mins by spectrophotometry | 2011 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24 | Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors. |
| AID711438 | Cytotoxicity against mouse P388 cells | 2012 | Journal of natural products, Nov-26, Volume: 75, Issue:11 | Lanostanoids from fungi: a group of potential anticancer compounds. |
| AID711439 | Cytotoxicity against human Bel7402 cells | 2012 | Journal of natural products, Nov-26, Volume: 75, Issue:11 | Lanostanoids from fungi: a group of potential anticancer compounds. |
| AID711437 | Cytotoxicity against human SGC7901 cells | 2012 | Journal of natural products, Nov-26, Volume: 75, Issue:11 | Lanostanoids from fungi: a group of potential anticancer compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||